Mean Rise in Hemoglobin After Intravenous Iron Therapy in Children with Iron Deficiency Anemia

Ammara Mushtaq Khan, Sughra Zulfiqar, Amna Saleem, Fahim Ahmed Subhani, Ammara Ayub, Tahira Khurram
{"title":"Mean Rise in Hemoglobin After Intravenous Iron Therapy in Children with Iron Deficiency Anemia","authors":"Ammara Mushtaq Khan, Sughra Zulfiqar, Amna Saleem, Fahim Ahmed Subhani, Ammara Ayub, Tahira Khurram","doi":"10.47489/szmc.v38i1.414","DOIUrl":null,"url":null,"abstract":"Introduction: Iron deficiency anemia (IDA) is a significant public health issue in Pakistan, affecting up to 63% of children, as revealed by the Pakistan National Nutritional Survey 2018. While oral iron remains the primary choice, challenges in compliance have led to the consideration of intravenous (IV) iron therapy, particularly iron sucrose. The study discusses the safety and efficacy of IV iron therapy in Pakistani children and aims to broaden our understanding of treating IDA in resource-constrained regions.\nAims & Objectives: To determine the average hemoglobin (Hb) increase in iron-deficient-anemic children aged 01 to 12 years after treatment with intravenous iron sucrose.\nPlace and Duration of Study: A quasi-experimental study was undertaken at Fauji Foundation Hospital in Rawalpindi, spanning from September 2021 to September 2022.\nMaterial & Methods: The study focused on a cohort of pediatric patients aged between 1 and 12 years, all of whom were diagnosed with iron deficiency anemia and had previously encountered ineffective outcomes with oral iron therapy. In this investigation, the patients received treatment involving intravenous iron sucrose. Subsequently, their progress was diligently monitored after a period of 8 weeks. Improvement in hemoglobin level was assessed at the end of treatment to evaluate its efficacy.Data processing and statistical analysis were carried out using SPSS version 23,p-value of <0.05 indicated statistical significance.\nResults: Out of 150 study cases, 96 (64.0 %) were male, while 54 (36.0 %) were female. The mean age of our study cases was 05 ± 2.3 years of these 150 study cases, 74 (49.3 %) belonged to rural areas, and 76 (50.7 %) belonged to urban areas. Poor socioeconomic status was noted in 97 (64.7 %), and 53 (35.3%) were middle-income. A family history of iron deficiency anaemia was recorded in 16 (10.7%). Iron deficiency due to dietary iron insufficiency was reported in 67 (44.7%), Total Parentral Nutrition (TPN) dependencywas seen in 61 (40.7%) and 22 (14.7%) had chronic gastritis. The mean baseline (pretreatment) haemoglobin level was 7.71 ± 0.63 g/dl, while the mean post-treatment haemoglobin level was 10.68 ± 0.60 g / dl (p = 0.001).\nConclusion: After intravenous iron sucrose, we noted a significant rise in paediatric patients' hemoglobin levels, emphasizing its effectiveness and safety. Statistically, we found correlations with age, family history, and causes. Healthcare practitioners should consider injectable iron treatments for better results and reduced health issues in this group.","PeriodicalId":20443,"journal":{"name":"Proceedings","volume":"48 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47489/szmc.v38i1.414","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Iron deficiency anemia (IDA) is a significant public health issue in Pakistan, affecting up to 63% of children, as revealed by the Pakistan National Nutritional Survey 2018. While oral iron remains the primary choice, challenges in compliance have led to the consideration of intravenous (IV) iron therapy, particularly iron sucrose. The study discusses the safety and efficacy of IV iron therapy in Pakistani children and aims to broaden our understanding of treating IDA in resource-constrained regions. Aims & Objectives: To determine the average hemoglobin (Hb) increase in iron-deficient-anemic children aged 01 to 12 years after treatment with intravenous iron sucrose. Place and Duration of Study: A quasi-experimental study was undertaken at Fauji Foundation Hospital in Rawalpindi, spanning from September 2021 to September 2022. Material & Methods: The study focused on a cohort of pediatric patients aged between 1 and 12 years, all of whom were diagnosed with iron deficiency anemia and had previously encountered ineffective outcomes with oral iron therapy. In this investigation, the patients received treatment involving intravenous iron sucrose. Subsequently, their progress was diligently monitored after a period of 8 weeks. Improvement in hemoglobin level was assessed at the end of treatment to evaluate its efficacy.Data processing and statistical analysis were carried out using SPSS version 23,p-value of <0.05 indicated statistical significance. Results: Out of 150 study cases, 96 (64.0 %) were male, while 54 (36.0 %) were female. The mean age of our study cases was 05 ± 2.3 years of these 150 study cases, 74 (49.3 %) belonged to rural areas, and 76 (50.7 %) belonged to urban areas. Poor socioeconomic status was noted in 97 (64.7 %), and 53 (35.3%) were middle-income. A family history of iron deficiency anaemia was recorded in 16 (10.7%). Iron deficiency due to dietary iron insufficiency was reported in 67 (44.7%), Total Parentral Nutrition (TPN) dependencywas seen in 61 (40.7%) and 22 (14.7%) had chronic gastritis. The mean baseline (pretreatment) haemoglobin level was 7.71 ± 0.63 g/dl, while the mean post-treatment haemoglobin level was 10.68 ± 0.60 g / dl (p = 0.001). Conclusion: After intravenous iron sucrose, we noted a significant rise in paediatric patients' hemoglobin levels, emphasizing its effectiveness and safety. Statistically, we found correlations with age, family history, and causes. Healthcare practitioners should consider injectable iron treatments for better results and reduced health issues in this group.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
缺铁性贫血儿童接受静脉铁剂治疗后血红蛋白的平均升幅
导言:缺铁性贫血(IDA)是巴基斯坦的一个重大公共卫生问题,根据 2018 年巴基斯坦全国营养调查显示,受其影响的儿童高达 63%。虽然口服铁剂仍是主要选择,但依从性方面的挑战导致人们开始考虑静脉注射(IV)铁剂疗法,尤其是蔗糖铁剂。本研究讨论了静脉注射铁剂疗法在巴基斯坦儿童中的安全性和有效性,旨在拓宽我们对在资源有限地区治疗 IDA 的理解:确定 01 至 12 岁缺铁性贫血儿童在接受蔗糖铁静脉注射治疗后血红蛋白(Hb)的平均增幅:在拉瓦尔品第的 Fauji 基金会医院开展了一项准实验研究,时间跨度为 2021 年 9 月至 2022 年 9 月:研究对象为年龄在 1 到 12 岁之间的儿童患者,他们都被诊断为缺铁性贫血,之前接受口服铁剂治疗效果不佳。在这项调查中,患者接受了蔗糖铁静脉注射治疗。随后,在 8 周后对他们的病情进展进行了认真监测。数据处理和统计分析采用 SPSS 23 版本,P 值小于 0.05 表示有统计学意义:在 150 例研究病例中,96 例(64.0%)为男性,54 例(36.0%)为女性。研究病例的平均年龄为(05 ± 2.3)岁,其中 74 例(49.3%)属于农村地区,76 例(50.7%)属于城市地区。97人(64.7%)的社会经济状况较差,53人(35.3%)属于中等收入阶层。16人(10.7%)有缺铁性贫血家族史。67人(44.7%)因膳食铁不足而缺铁,61人(40.7%)依赖全胃肠道营养(TPN),22人(14.7%)患有慢性胃炎。基线(治疗前)血红蛋白平均水平为 7.71 ± 0.63 g/dl,而治疗后血红蛋白平均水平为 10.68 ± 0.60 g/dl(P = 0.001):我们注意到,静脉注射蔗糖铁后,儿科患者的血红蛋白水平有了显著提高,强调了其有效性和安全性。从统计学角度看,我们发现这与年龄、家族史和病因有关。医护人员应考虑采用注射铁剂治疗,以取得更好的效果,减少该群体的健康问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
1
审稿时长
11 weeks
期刊最新文献
Prevalence of Secondary Hyperparathyroidism in Hemo- Dialysis Patients Mean Rise in Hemoglobin After Intravenous Iron Therapy in Children with Iron Deficiency Anemia Mean Rise in Hemoglobin After Intravenous Iron Therapy in Children with Iron Deficiency Anemia Estimation of Rotavirus Associated Diarrheal Disease Burden Amongst Primary School Children of Sindh Functional Outcome of Shaft of Femur Fracture Fixation with Elastic Nail in Children Between 05 to 10 Years of Age
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1